March 2 (Reuters) – Eli Lilly CFO Lucas Montarce said on Monday it is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as the second quarter of this year, once it gets approval from the Food and Drug Administration. “On track in the US, expect to see potentially […]
Health
Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval
Audio By Carbonatix
March 2 (Reuters) – Eli Lilly CFO Lucas Montarce said on Monday it is preparing to launch its new oral obesity drug, orforglipron, in the United States as early as the second quarter of this year, once it gets approval from the Food and Drug Administration.
“On track in the US, expect to see potentially that product coming into the market as early as Q2,” Montarce said at the TD Cowen healthcare conference.
* Lilly said the review is progressing as expected and addedthat “nothing has changed” in its confidence that the FDA willissue a decision in April. * Montarce said it can begin shipping the pill within abouta week after approval, allowing a quick rollout to U.S.patients. * Last month, Lilly said it had $1.5 billion worth ofpre-launch inventory of its pill. * The drug will face competition from Novo Nordisk’s Wegovypill, the first oral GLP‑1 drug for weight loss that waslaunched in the U.S. in January. * Lilly added that it has already prepared for fullcommercial distribution and is in talks with pharmacy benefitmanagers to secure coverage. * For markets outside the United States, broad access isexpected around 2027.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shinjini Ganguli)